Teva to Hold Generic Opioid Addiction Drug Launch Pending U.S. Ruling

The Israeli pharmaceutical giant in engaged in a legal battle over the release of Suboxone Film, an opioid addiction drug

A building belonging to Teva Pharmaceutical Industries, the world's biggest generic drugmaker, is seen in Jerusalem February 8, 2017.
REUTERS/Ronen Zvulun/File Photo

Teva Pharmaceuticals has agreed to hold off launching its knock-off version of Indivior Plc’s blockbuster opioid addiction drug until the resolution of a U.S. Court case on another generic rival, Indivior said on Wednesday.

The pair’s Indian rival Dr. Reddy’s Laboratories is currently locked in a legal battle in the United States to re-launch a cheaper version of the UK drugmaker’s Suboxone Film.

Indivior also reiterated its full-year net revenues guidance of $25 million to $50 million from its new opioid addiction drug Sublocade, on which the company has pinned its hopes after the legal battles.